Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 1/2016

01-01-2016 | Research Article

Salinomycin radiosensitizes human nasopharyngeal carcinoma cell line CNE-2 to radiation

Authors: Yongqin Zhang, Yun Zuo, Zhifeng Guan, Weidong Lu, Zheng Xu, Hao Zhang, Yan Yang, Meilin Yang, Hongcheng Zhu, Xiaochen Chen

Published in: Tumor Biology | Issue 1/2016

Login to get access

Abstract

Nasopharyngeal carcinoma (NPC) is primarily treated by chemoradiation. However, how to promote radiation sensitivity in NPC remains a challenge. Salinomycin is potentially useful for the treatment of cancer. This study aimed to explore the radiosensitivity of salinomycin on human nasopharyngeal carcinoma cell line CNE-2. CNE-2 were treated with salinomycin or irradiation, alone or in combination. The cytotoxicity effects of salinomycin were measured using CCK-8 assay. Clonogenic survival assay was used to evaluate the effects of salinomycin on the radiosensitivity of CNE-2. The changes of cell cycle distribution and apoptosis were assayed using flow cytometry. The expression of Caspase3/Bax/Bal-2 was detected by Western blotting. DNA damage was detected via γ-H2AX foci counting. The results showed that salinomycin induced apoptosis and G2/M arrest, increased Bax and cleaved Caspase3, decreased Bcl-2 expression, and increased the formation of γ-H2AX nuclear foci. These data suggest that salinomycin may be a radiosensitizer for NPC radiotherapy.
Literature
1.
Akervall J, Nandalur S, Zhang J, Qian CN, Goldstein N, Gyllerup P, et al. A novel panel of biomarkers predicts radioresistance in patients with squamous cell carcinoma of the head and neck. Eur J Cancer. 2014;50(3):570–81.CrossRefPubMed
2.
Miyazaki Y, Shibuya M, Sugawara H, Kawaguchi O, Hirsoe C. Salinomycin, a new polyether antibiotic. J Antibiot Tokyo. 1974;27(11):814–21.CrossRefPubMed
3.
Mahmoudi N, de Julián-Ortiz JV, Ciceron L, Gálvez J, Mazier D, Danis M, et al. Identification of new antimalarial drugs by linear discriminant analysis and topological virtual screening. J Antimicrob Chemother. 2006;57(3):489–97.CrossRefPubMed
4.
Danforth HD, Ruff MD, Reid WM, Johnson J. Anticoccidial activity of salinomycin in floor-pen experiments with broilers. Poult Sci. 1977;56(3):933–8.CrossRefPubMed
5.
Gupta PB, Onder TT, Jiang G, Tao K, Kuperwasser C, Weinberg RA, et al. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell. 2009;138(4):645–59.CrossRefPubMedPubMedCentral
6.
Zhi QM, Chen XH, Ji J, Zhang JN, Li JF, Cai Q, et al. Salinomycin can effectively kill ALDH (high) stem-like cells on gastric cancer. Biomed Pharmacother. 2011;65(7):509–15.CrossRefPubMed
7.
He L, Wang F, Dai WQ, Wu D, Lin CL, Wu SM, et al. Mechanism of action of salinomycin on growth and migration in pancreatic cancer cell lines. Pancreatology. 2013;13(1):72–8.CrossRefPubMed
8.
Zhang GN, Liang Y, Zhou LJ, Chen SP, Chen G, Zhang TP, et al. Combination of salinomycin and gemcitabine eliminates pancreatic cancer cells. Cancer Lett. 2011;313(2):137–44.CrossRefPubMed
9.
Wang F, He L, Dai WQ, Xu YP, Wu D, Lin CL, et al. Salinomycin inhibits proliferation and induces apoptosis of human hepatocellular carcinoma cells in vitro and in vivo. PLoS One. 2012;7(12):e50638.CrossRefPubMedPubMedCentral
10.
Zhang B, Wang X, Cai F, Chen W, Loesch U, Bitzer J, et al. Effects of salinomycin on human ovarian cancer cell line OV2008 are associated with modulating p38 MAPK. Tumour Biol. 2012;33(6):1855–62.CrossRefPubMed
11.
Ketola K, Hilvo M, Hyötyläinen T, Vuoristo A, Ruskeepää AL, Orešič M, et al. Salinomycin inhibits prostate cancer growth and migration via induction of oxidative stress. Br J Cancer. 2012;106(1):99–106.CrossRefPubMedPubMedCentral
12.
Kim KY, Yu SN, Lee SY, Chun SS, Choi YL, Park YM, et al. Salinomycin-induced apoptosis of human prostate cancer cells due to accumulated reactive oxygen species and mitochondrial membrane depolarization. Biochem Biophys Res Commun. 2011;413(1):80–6.CrossRefPubMed
13.
Kuo SZ, Blair KJ, Rahimy E, Kiang A, Abhold E, Fan JB, et al. Salinomycin induces cell death and differentiation in head and neck squamous cell carcinoma stem cells despite activation of epithelial-mesenchymal transition and Akt. BMC Cancer. 2012;12:556.CrossRefPubMedPubMedCentral
14.
Scherzed A, Hackenberg S, Froelich K, Rak K, Technau A, Radeloff A, et al. Effects of salinomycin on human bone marrow-derived mesenchymal stem cells in vitro. Toxicol Lett. 2013;218(3):207–14.CrossRefPubMed
15.
Fuchs D, Heinold A, Opelz G, Daniel V, Naujokat C. Salinomycin induces apoptosis and overcomes apoptosis resistance in human cancer cells. Biochem Biophys Res Commun. 2009;390(3):743–9.CrossRefPubMed
16.
Fuchs D, Daniel V, Sadeghi M, Opelz G, Naujokat C. Salinomycin overcomes ABC transporter-mediated multidrug and apoptosis resistance in human leukemia stem cell-like KG-1a cells. Biochem Biophys Res Commun. 2010;394(4):1098–104.CrossRefPubMed
17.
Riccioni R, Dupuis ML, Bernabei M, Petrucci E, Pasquini L, Mariani G, et al. The cancer stem cell selective inhibitor salinomycin is a p-glycoprotein inhibitor. Blood Cells Mol Dis. 2010;45(1):86–92.CrossRefPubMed
18.
Wang Y. Effects of salinomycin on cancer stem cell in human lung adenocarcinoma A549 cells. Med Chem. 2011;7(2):106–11.CrossRefPubMed
19.
Dong TT, Zhou HM, Wang LL, Feng B, Lv B, Zheng MH. Salinomycin selectively targets ‘CD133+’ cell subpopulations and decreases malignant traits in colorectal cancer lines. Ann Surg Oncol. 2011;18(6):1797–804.CrossRefPubMed
20.
Zhang C, Yang X, Zhang Q, Yang B, Xu L, Qin Q, et al. Berberine radiosensitizes human nasopharyngeal carcinoma by suppressing hypoxia-inducible factor-1α expression. Acta Otolaryngol. 2014;134:185–92.CrossRefPubMed
21.
Kim JH, Chae M, Kim WK, Kim YJ, Kang HS, Kim HS, et al. Salinomycin sensitizes cancer cells to the effects of doxorubicin and etoposide treatment by increasing DNA damage and reducing p21 protein. Br J Pharmacol. 2011;162(3):773–84.CrossRefPubMedPubMedCentral
22.
Verdoodt B, Vogt M, Schmitz I, Liffers ST, Tannapfel A, Mirmohammadsadegh A. Salinomycin induces autophagy in colon and breast cancer cells with concomitant generation of reactive oxygen species. PLoS One. 2012;7(9):e44132.CrossRefPubMedPubMedCentral
23.
Le PN, McDermott JD, Jimeno A. Targeting the Wnt pathway in human cancers: therapeutic targeting with a focus on OMP-54f28. Pharmacol Ther. 2015;146:1–11.CrossRefPubMed
Metadata
Title
Salinomycin radiosensitizes human nasopharyngeal carcinoma cell line CNE-2 to radiation
Authors
Yongqin Zhang
Yun Zuo
Zhifeng Guan
Weidong Lu
Zheng Xu
Hao Zhang
Yan Yang
Meilin Yang
Hongcheng Zhu
Xiaochen Chen
Publication date
01-01-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 1/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-3730-6

Other articles of this Issue 1/2016

Tumor Biology 1/2016 Go to the issue

Original Article

Inverse regulation of bridging integrator 1 and BCR-ABL1 in chronic myeloid leukemia

Original Article

The 811 C/T polymorphism in the 3′ untranslated region of the selenoprotein 15-kDa (Sep15) gene and breast cancer in Caucasian women

Original Article

Prognostic analysis of primary mucin-producing adenocarcinoma of the lung: a comprehensive retrospective study

Review

The role of TWIST1 in epithelial-mesenchymal transition and cancers

Original Article

Strong expression of polypeptide N-acetylgalactosaminyltransferase 3 independently predicts shortened disease-free survival in patients with early stage oral squamous cell carcinoma

Original Article

CXCL12-CXCR4/CXCR7 axis contributes to cell motilities of oral squamous cell carcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits